Zura Bio Limited closed at $4.02 on Nov 4, up 0.75%, 42.9% below its 52-week closing high. Volume of 2.0M shares was 0.38× its 20-day average (below normal).
Split-adjusted performance: +1.5% over one month, -17.8% over six months, +9.2% over one year.
Short interest was 7.0M shares at the Oct 15 settlement, down 25.1% from the prior report (12.7% of float, 1.5 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ZURAZura Bio Limited | $4.02 | +0.75% | −17.8% | — | — | — | $387.2M | |
| CCCCC4 Therapeutics | $3.12 | −2.80% | +6.5% | +2.8% | −355.9% | — | $383.8M | Compare |
| TECXTectonic Therapeutic | $20.30 | +6.95% | −30.0% | — | — | — | $396.9M | Compare |
| SRZNSurrozen | $31.65 | +5.08% | −7.3% | +408.6% | 640.8% | — | $372.0M | Compare |
| ALLOAllogene Therapeutics | $1.19 | +6.25% | −48.5% | — | −919.8% | — | $411.1M | Compare |
| FENCFennec Pharmaceuticals | $10.35 | −3.27% | +44.2% | +85.2% | 11.0% | — | $362.9M | Compare |
| EDITEditas Medicine | $2.72 | +4.62% | −14.3% | +232.3% | −153.3% | — | $417.7M | Compare |
| EIKNEikon Therapeutics | $6.39 | +15.14% | −35.9% | — | — | — | $346.1M | Compare |
| XFORX4 Pharmaceuticals | $3.24 | +2.21% | −26.0% | +346.3% | −183.5% | — | $321.2M | Compare |
No recent articles focused on Zura Bio Limited. 1 articles mention it in passing.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
